登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
ClinicalTrials.gov 上登记的一项脊髓性肌萎缩症开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06421831,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 3
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(3 项)收起清单
2 岁 至 未注明;性别:不限
登记记录的入选字段
Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients (both male and female), should take effective contraceptive measures within 6 months after the treatment;
入选标准第 4 条
Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment;
排除标准第 3 条
Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06421831,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
≥2 years of age on the day of signing the informed consent form; Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA; Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening; Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients (both male and female), should take effective contraceptive measures within 6 months after the treatment; Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.排除标准:Exclusion Criteria:
Patient who has participated in any previous gene therapy research trials; Patient who has AAV9 neutralizing antibody titer ≥1:200; Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment; Patient who requires invasive or non-invasive ventilatory support averaging≥16 hours/day at screening; SMN2 copy numbers >4; Patient who needs nasal or gastric tube feeding for eating; Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody; Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients Severe contractures at screening that interfere with either the ability to attain/demonstrate functional measures or with the ability to receive intrathecal (IT) dosing; Patient who has other serious diseases, such as severe cardiovascular and cerebrovascular diseases, digestive system diseases, urinary system diseases, endocrine system diseases, hematological diseases, immune system diseases, nervous system diseases (including but not limited to epilepsy, meningitis, history of convulsions or seizures, cerebrospinal fluid circulation disorders), and mental illnesses, etc.; Patient with previous injuries (such as upper or lower limb fractures) or surgical operations that have not fully recovered or reached a stable state; Vaccination no longer than 2 weeks before treatment; Patient who has any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
引自 ClinicalTrials.gov, NCT06421831, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06421831,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。